Du, KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol, 2012. 18(37): p. 5171-80.Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol 2012;18:5171-80.Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World ...
1、Ros J, Vaghi C, Baraibar I, Saoudi González N, Rodríguez-Castells M, García A, Alcaraz A, Salva F, Tabernero J, Elez E. Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. Int J Mol Sci. 2024 Mar 14;25(6):3304. doi: 10.3390/ijms250633...
[1]Jänne PA, Riely G, Gadgee SM等人。‘Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation’,《N Engl J Med》；2022;386:22. doi:10.1056/NEJMoa2204619.[2]Gadgeel SM, Jänne PA, Spira AI等人。‘KRYSTAL-1: two-year follow-up of adagrasib (MRTX849) monoth...
OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of MetastaticColorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome inpatients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-linetherapy for metastatic co...
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021). KRAS mutation: from undruggable to druggable in cancer. Signal Transduction and Targeted Therapy, 6(1), 386. https://doi.org/10.1038/s41392-021-00780-4 Jančík, S., Drábek, J., Radzioch, D., & Hajdúch, M. (2010). ...
GENETIC mutationBONE metastasisCOLON cancerALKALINE phosphataseMEDICAL statisticsBone metastasis is known as a poor prognostic factor in colorectal cancer (CRC), but its clinical manifestations and outcomes are uncertain. CRC with bone metastasis was searched from January 2006 to April 2016. Of 11,551 ...
然而，由于KRAS蛋白表面缺乏可供药物结合的口袋，直接针对其突变进行药物靶向治疗一直是个难题。其中，KRAS p.G12C突变体由于其在结构和功能上的特殊性，成为研究的热点和治疗的难点。鉴于此，2023年7月，《Cancers》杂志发表的一篇题为《KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications...
[2]Targe ting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver, International Journal of Molecular Science, Mar. 2024 本文由药明康德内容团队根据公开资料整理编辑,欢迎个人转发至朋友圈。转发授权请在「医药观澜」微信公众号留言联系我们。其他合作需求,请联系wuxi_media@wuxiapp...
[8] Yuan Y, Liu Y, Wu Y, et al. Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients. Int J Biol Markers. 2021;36(2):33-39. doi:10.1177/17246008211017152 [9] ...
[3]Pant S, Yaeger R, Spira AI, et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol. 2023;41(suppl 36):425082. doi:10.1200/JCO.2023.41.36_suppl.425082 ...